A targeted expression panel for classification, gene fusion detection and PD-L1 measurements – Can molecular profiling replace immunohistochemistry in non-small cell lung cancer?

Simonsen, Anita Tranberg; Utke, A.; Lade-Keller, Johanne; Thomsen, Lasse Westphal; Steiniche, Torben; Stougaard, Magnus

doi:10.1016/j.yexmp.2022.104749

Experimental and Molecular Pathology

2022

DOI: 10.1016/j.yexmp.2022.104749

|View full text |Cite

A targeted expression panel for classification, gene fusion detection and PD-L1 measurements – Can molecular profiling replace immunohistochemistry in non-small cell lung cancer?

Anita Tranberg Simonsen

A. Utke

Johanne Lade-Keller

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

2024

Publication Types

Select...

Article4

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Current status and progress of PD-L1 detection: guiding immunotherapy for non-small cell lung cancer

Qi,

Li,

Zeng

et al. 2024

Clin Exp Med

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths and represents a substantial disease burden worldwide. Immune checkpoint inhibitors combined with chemotherapy are the standard first-line therapy for advanced NSCLC without driver mutations. Programmed death-ligand 1 (PD-L1) is currently the only approved immunotherapy marker. PD-L1 detection methods are diverse and have developed rapidly in recent years, such as improved immunohistochemical detection methods, the application of liquid biopsy in PD-L1 detection, genetic testing, radionuclide imaging, and the use of machine learning methods to construct PD-L1 prediction models. This review focuses on the detection methods and challenges of PD-L1 from different sources, and discusses the influencing factors of PD-L1 detection and the value of combined biomarkers. Provide support for clinical screening of immunotherapy-advantage groups and formulation of personalized treatment decisions.

show abstract

Current status and progress of PD-L1 detection: guiding immunotherapy for non-small cell lung cancer

Qi,

Li,

Zeng

et al. 2024

Clin Exp Med

View full text Add to dashboard Cite

show abstract

Potential biomarkers for immunotherapy in non-small-cell lung cancer

Wang

Qiao

Aramini

et al. 2023

Cancer Metastasis Rev

View full text Add to dashboard Cite

Enhancing anti-CD274 (PD-L1) targeting through combinatorial immunotherapy with bispecific antibodies and fusion proteins: from preclinical to phase II clinical trials

Kiem,

Ocker,

Greil

et al. 2024

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

A targeted expression panel for classification, gene fusion detection and PD-L1 measurements – Can molecular profiling replace immunohistochemistry in non-small cell lung cancer?

Cited by 4 publications

References 30 publications

Current status and progress of PD-L1 detection: guiding immunotherapy for non-small cell lung cancer

Current status and progress of PD-L1 detection: guiding immunotherapy for non-small cell lung cancer

Potential biomarkers for immunotherapy in non-small-cell lung cancer

Enhancing anti-CD274 (PD-L1) targeting through combinatorial immunotherapy with bispecific antibodies and fusion proteins: from preclinical to phase II clinical trials

Contact Info

Product

Resources

About